American Society of Hematology

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.


Blood is the official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December, in addition to the ASH Annual Meeting Abstracts issue in November.

Research Programs and Awards

Explore programs offered by ASH to support clinical and scientific hematology research

Hematology Research Agenda

ASH's strategic plan highlighting the importance of placing hematology as a top funding priority in the healthcare community

  • More Evidence Supporting a Conservative Approach to Red Blood Cell Transfusion

    Although the Transfusion Requirements in Critical Care (TRICC) trial showed the benefits of a conservative transfusion strategy more than 15 years ago, many physicians remain skeptical about the safety of lower hemoglobin thresholds for red cell transfusion in critically ill patients.

  • Variation in Cancer Risk: Nature, Nurture, and Random Chance

    While it is commonly understood that the environment and heredity contribute to the development of cancer, what if something else contributed to carcinogenesis?

  • Factor XI Antisense: A Challenge to Common Sense

    Animal studies suggest that inhibition of factor XI (FXI) prevents thrombosis without disrupting hemostasis. Epidemiologic data indicate that patients with congenital FXI deficiency are protected from venous thromboembolism (VTE), even though their bleeding phenotype is variable and often quite mild.

  • H3K27 Demethylases: A New Therapeutic Target in T-ALL?

    T-cell acute lymphoblastic leukemia (T-ALL) represents 10 to 15 percent of newly diagnosed cases of acute leukemia and is notable for its distinctive biological features and aggressive clinical course. While outcomes were once inferior, they now approach those observed in B-lymphoblastic disease (B-ALL).

View all Diffusion articles
View all policy news
back to top